| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.2009.79 |
| P698 | PubMed publication ID | 19474787 |
| P50 | author | Pertti J. Neuvonen | Q23039874 |
| Mikko Niemi | Q42328966 | ||
| Oliver Zolk | Q42731798 | ||
| P2093 | author name string | M F Fromm | |
| K J Kurkinen | |||
| J E Keskitalo | |||
| P2860 | cites work | Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study | Q24318894 |
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Single nucleotide polymorphisms modify the transporter activity of ABCG2. | Q33214177 | ||
| Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe | Q33704930 | ||
| Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants | Q33776950 | ||
| Statin-associated myopathy | Q34187996 | ||
| Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy | Q34536592 | ||
| SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers | Q34579035 | ||
| Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance | Q34592657 | ||
| Importance of P-glycoprotein at blood-tissue barriers | Q35847121 | ||
| The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). | Q36052743 | ||
| Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered | Q36186431 | ||
| Role of OATP transporters in the disposition of drugs | Q37074085 | ||
| Functional analysis of SNPs variants of BCRP/ABCG2. | Q38334083 | ||
| Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. | Q40171501 | ||
| ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein | Q40328998 | ||
| Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment | Q40435868 | ||
| Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin | Q42438441 | ||
| Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein | Q42494665 | ||
| Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection | Q43991035 | ||
| Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. | Q44747134 | ||
| Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner | Q44842291 | ||
| Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype | Q44960521 | ||
| Lipid-lowering response to statins is affected by CYP3A5 polymorphism | Q45000633 | ||
| Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver | Q45275828 | ||
| ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. | Q46111557 | ||
| Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. | Q46525793 | ||
| ATP-binding cassette transporters in human heart failure | Q46661337 | ||
| Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms | Q46809845 | ||
| Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans | Q46826559 | ||
| The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment | Q46830670 | ||
| Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein | Q47725118 | ||
| Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. | Q52086788 | ||
| Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males | Q57500331 | ||
| Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin | Q57825140 | ||
| SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Q57825144 | ||
| SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin | Q57825149 | ||
| Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population | Q57825157 | ||
| Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry | Q77882399 | ||
| Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2) | Q81235097 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 197-203 | |
| P577 | publication date | 2009-05-27 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | |
| P478 | volume | 86 |
| Q90020619 | A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites |
| Q97684348 | A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment |
| Q37050337 | A perspective on efflux transport proteins in the liver |
| Q35917726 | A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. |
| Q30313271 | ABC Transport Proteins in Cardiovascular Disease-A Brief Summary |
| Q38107993 | ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. |
| Q36050960 | ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population |
| Q43174441 | ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin |
| Q60916021 | ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics |
| Q40916355 | Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins |
| Q89335175 | Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects |
| Q57825111 | Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans |
| Q54053216 | Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. |
| Q37579733 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care |
| Q38160088 | Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions |
| Q37881964 | Clinical response to statins: mechanism(s) of variable activity and adverse effects |
| Q40650613 | Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. |
| Q36796490 | Current Perspectives on rosuvastatin |
| Q38874222 | Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. |
| Q42917105 | Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite |
| Q43258273 | Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin |
| Q37392745 | Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. |
| Q37945657 | Drug safety evaluation of rosuvastatin |
| Q37793056 | Drug transport by breast cancer resistance protein. |
| Q36951933 | Drug-drug interaction studies: regulatory guidance and an industry perspective |
| Q38109095 | Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. |
| Q39985485 | Dyslipidemia in Special Ethnic Populations |
| Q35573543 | Dyslipidemia in special ethnic populations |
| Q54006194 | Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. |
| Q51304354 | Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome. |
| Q37017426 | Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. |
| Q50108375 | Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients. |
| Q51266635 | Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers. |
| Q38071700 | Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications |
| Q36620076 | Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies |
| Q46062183 | Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients |
| Q57500258 | Effects ofGinkgo bilobaextracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices |
| Q37724381 | Efflux and uptake transporters as determinants of statin response. |
| Q35183649 | Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers |
| Q93119620 | Enantiospecific Pharmacogenomics of Fluvastatin |
| Q38084901 | Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism |
| Q44737065 | Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans |
| Q30582571 | Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design |
| Q38155218 | Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin |
| Q48811919 | Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. |
| Q38707798 | Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis |
| Q36733503 | Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter |
| Q38613161 | Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity |
| Q26823434 | Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review |
| Q36998199 | Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 |
| Q37331801 | Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes |
| Q37331821 | Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. |
| Q38985192 | High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next? |
| Q37533506 | Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations |
| Q53611791 | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? |
| Q85432136 | Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women |
| Q91906950 | Impact of NR1I2, adenosine triphosphate-binding cassette transporters genetic polymorphisms on the pharmacokinetics of ginsenoside compound K in healthy Chinese volunteers |
| Q38663481 | Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. |
| Q37855801 | Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins |
| Q38888369 | Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? |
| Q38003174 | Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. |
| Q38888365 | Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites |
| Q36108251 | Improving cancer chemotherapy with modulators of ABC drug transporters |
| Q38214334 | In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery |
| Q35915932 | Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions |
| Q92132562 | Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects |
| Q60659111 | Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment |
| Q64062639 | Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications |
| Q39034284 | Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). |
| Q49546188 | Interindividual regulation of the BCRP/ABCG2 transporter in term human placentas. |
| Q45082643 | International Transporter Consortium commentary on clinically important transporter polymorphisms. |
| Q38379295 | Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles |
| Q37504548 | Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver |
| Q33581531 | Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin |
| Q38129422 | Lipid-lowing pharmacogenomics in Chinese patients |
| Q29616802 | Membrane transporters in drug development |
| Q40129655 | Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers |
| Q36958324 | Molecular mechanisms of statin intolerance |
| Q37394474 | More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. |
| Q89372273 | No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects |
| Q89100456 | PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling |
| Q46366046 | PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo |
| Q28068014 | Pediatric Statin Administration: Navigating a Frontier with Limited Data |
| Q38049379 | Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children |
| Q46018199 | PharmGKB summary: very important pharmacogene information for ABCG2. |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q53541756 | Pharmacogenomic diversity in Singaporean populations and Europeans. |
| Q37875115 | Pharmacogenomics and adverse drug reactions: the case of statins |
| Q38112823 | Pharmacogenomics of lipid-lowering therapies |
| Q53128063 | Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. |
| Q36110576 | Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. |
| Q42654776 | Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia |
| Q88061446 | Pharmacokinetic study of rosuvastatin in males and females |
| Q51516327 | Pharmacokinetics of intravenous paracetamol in elderly patients. |
| Q57684574 | Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions |
| Q39178447 | Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). |
| Q93098892 | Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion |
| Q37164563 | Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier |
| Q34571070 | Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin |
| Q38243832 | Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance |
| Q46369173 | Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP). |
| Q38782604 | Prediction of atorvastatin plasmatic concentrations in healthy volunteers using integrated pharmacogenetics sequencing. |
| Q30244632 | Racial Differences in the Cholesterol-Lowering Effect of Statin |
| Q30616911 | Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective |
| Q57463134 | Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies |
| Q39140289 | Renal Drug Transporters and Drug Interactions |
| Q46109720 | Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response |
| Q89022021 | Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence |
| Q34871636 | Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update |
| Q46204648 | Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. |
| Q41512597 | Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States |
| Q89642081 | Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease |
| Q50749129 | Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. |
| Q38207943 | Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics |
| Q34176588 | Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). |
| Q37810986 | The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins |
| Q28554497 | The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay |
| Q53736039 | The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein. |
| Q34968909 | The challenge of exploiting ABCG2 in the clinic. |
| Q92626380 | The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies |
| Q35478918 | The emerging role of electronic medical records in pharmacogenomics |
| Q37955160 | The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. |
| Q34613443 | The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. |
| Q26747187 | The multidrug transporter ABCG2: still more questions than answers |
| Q37986145 | Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee |
| Q40956563 | Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2. |
| Q53099537 | Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. |
| Q37627544 | Transporter pharmacogenetics and statin toxicity |
| Q45243894 | Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models |
| Q43268896 | UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo |
| Q46766214 | Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics |
| Q38050686 | Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. |
| Q38726643 | Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. |
| Q36571217 | What do drug transporters really do? |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
Search more.